Xcout IntelAffini-T Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Affini-T Therapeutics, Inc. among biotechnology companies — ranked by similarity to what Affini-T Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Affini-T Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Affini-T Therapeutics, Inc. at a glance
Affini-T Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $175M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $17.6M in October 2024. Xcout tracks 1 named person at Affini-T Therapeutics, Inc., including Joseph Knowles (Chief Executive Officer).
Affini-T Therapeutics, Inc. leadership
- Joseph KnowlesChief Executive Officer
Affini-T Therapeutics, Inc. funding rounds
At least $175M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $17.6M | 8 named | |
| Series A | $175M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Affini-T Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Affini-T Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Biotech
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Biotech
Mariana Oncology is a fully integrated radiopharmaceutical company headquartered in Watertown, Massachusetts, that develops precision radioligand therapies to transform cancer treatment.
Similar biotechnology company
Actithera, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on delivering targeted radioligand cancer therapies.
Similar biotechnology company
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Biotech
Immatics is a biopharmaceutical company that develops T cell-based immunotherapies and bispecific product candidates to treat various types of cancer. The company focuses on precision targeting of the PRAME protein expressed in multiple solid tumors, serving cancer patients with high unmet medical needs.
Similar biotechnology company
NextPoint Therapeutics is a private biopharmaceutical and technology company based in Cambridge, Massachusetts, focused on expanding novel therapeutic possibilities.
Similar biotechnology company
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
Biotech
ArsenalBio is a biotechnology company developing programmable cell therapies, particularly engineered T-cell therapies, for cancer treatment. It serves biopharmaceutical and healthcare markets by using synthetic biology and genomic engineering to create more effective, controllable immune-cell medicines.
Biotech
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Similar biotechnology company
Century Therapeutics is an innovative biotechnology company headquartered in Philadelphia, Pennsylvania. Its mission is to develop allogeneic, iPSC-derived NK and T cell therapies that are designed to be more effective, tolerable, and accessible.
Biotech
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Affini-T Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Affini-T Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →